Table 2.

Relapse of Hepatitis C Virus Infection in Patents Stratified by Fibroindex

Fibroindex	Low-dose group	High-dose group	Placebo	P1	P2
<1.40
No. of patients	9	10	10
No. of relaspers	2 (22.2%)	3 (30.0%)	2 (25.0%)	1.00	1.00
≥1.40, <1.70
No. of patients	12	9	12
No. of relaspers	1 (8.3%)	4 (44.4%)	5 (41.7%)	0.12	0.05
≥1.70, <2.0
No. of patients	20	15	20
No. of relaspers	8 (40.0%)	4 (26.7%)	6 (30.0%)	0.77	0.38
≥2.0
No. of patients	18	19	15
No. of relaspers	7 (38.9%)	9 (47.4%)	7 (46.7%)	0.85	0.57

P1, overall comparison; P2, low-dose group versus high-dose group plus placebo.